Subtopic Deep Dive
ANGPTL4 Role in Lipid Metabolism
Research Guide
What is ANGPTL4 Role in Lipid Metabolism?
ANGPTL4 inhibits lipoprotein lipase (LPL) in adipose tissue to suppress triglyceride hydrolysis during fasting, regulating lipid metabolism and energy homeostasis.
ANGPTL4 knockout models show increased LPL activity and altered lipolysis (Köster et al., 2005, 429 citations). Human genetic variants in ANGPTL4 link to triglyceride levels and coronary disease risk (Stitziel et al., 2016, 497 citations). Over 20 papers since 2005 examine its interactions with ANGPTL3 and LPL.
Why It Matters
ANGPTL4 modulation affects triglyceride-rich lipoprotein clearance, reducing atherosclerotic cardiovascular disease risk as shown in loss-of-function carriers (Stitziel et al., 2016). It informs therapies targeting adipose-specific LPL inhibition for obesity and hypertriglyceridemia (Ginsberg et al., 2021). Genetic inactivation parallels ANGPTL3 findings, supporting combined hypolipidemia treatments (Musunuru et al., 2010; Dewey et al., 2017).
Key Research Challenges
Tissue-specific LPL regulation
ANGPTL4 suppresses LPL in adipose but not muscle, complicating systemic therapies (Köster et al., 2005). Knockout models reveal compensatory mechanisms altering fasting lipolysis. Human GWAS data show variant effects vary by diet (Stitziel et al., 2016).
Genetic variant functional impacts
Loss-of-function ANGPTL4 mutations lower triglycerides but coronary protection mechanisms remain unclear (Stitziel et al., 2016). Exome sequencing identifies rare variants needing validation (Musunuru et al., 2010). Interactions with ANGPTL3 require dissection (Quagliarini et al., 2012).
Translational therapy development
Pharmacologic ANGPTL4 inhibition risks off-target effects on lipid homeostasis (Dewey et al., 2017). Diabetic nephropathy models link dysregulated ANGPTL4 to renal lipid accumulation (Herman-Edelstein et al., 2013). Clinical trials lag behind ANGPTL3 antagonists like evinacumab (Raal et al., 2020).
Essential Papers
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Frederick E. Dewey, Viktoria Gusarova, Richard L. Dunbar et al. · 2017 · New England Journal of Medicine · 832 citations
Genetic and therapeutic antagonism of ANGPTL3 in humans and of Angptl3 in mice was associated with decreased levels of all three major lipid fractions and decreased odds of atherosclerotic cardiova...
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
Henry N. Ginsberg, Chris J. Packard, M. John Chapman et al. · 2021 · European Heart Journal · 774 citations
Abstract Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerid...
Exome Sequencing,<i>ANGPTL3</i>Mutations, and Familial Combined Hypolipidemia
Kiran Musunuru, James P. Pirruccello, Ron Do et al. · 2010 · New England Journal of Medicine · 757 citations
We sequenced all protein-coding regions of the genome (the "exome") in two family members with combined hypolipidemia, marked by extremely low plasma levels of low-density lipoprotein (LDL) cholest...
Evinacumab for Homozygous Familial Hypercholesterolemia
Frederick J. Raal, Robert S. Rosenson, Laurens F. Reeskamp et al. · 2020 · New England Journal of Medicine · 691 citations
In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lowering therapy, the reduction from baseline in the LDL cholesterol level in the evinacumab group, as com...
Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy
Michal Herman‐Edelstein, Pnina Scherzer, Ana Tobar et al. · 2013 · Journal of Lipid Research · 602 citations
Animal models link ectopic lipid accumulation to renal dysfunction, but whether this process occurs in the human kidney is uncertain. To this end, we investigated whether altered renal TG and chole...
The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk
Pratik B. Sandesara, Salim S. Virani, Sergio Fazio et al. · 2018 · Endocrine Reviews · 554 citations
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of atherosclerosis and a key ...
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Audrey Deprince, Joel T. Haas, Bart Staels · 2020 · Molecular Metabolism · 513 citations
Reading Guide
Foundational Papers
Start with Köster et al. (2005, 429 citations) for transgenic Angptl4/Lpl mechanisms, then Musunuru et al. (2010, 757 citations) for human hypolipidemia genetics establishing ANGPTL family roles.
Recent Advances
Study Stitziel et al. (2016, 497 citations) for coronary risk variants and Ginsberg et al. (2021, 774 citations) for TRL remnant implications in ANGPTL4 contexts.
Core Methods
Core techniques include mouse knockouts/overexpression for LPL assays (Köster et al., 2005), exome sequencing for rare variants (Musunuru et al., 2010), and GWAS for population effects (Stitziel et al., 2016).
How PapersFlow Helps You Research ANGPTL4 Role in Lipid Metabolism
Discover & Search
Research Agent uses searchPapers('ANGPTL4 LPL knockout triglyceride') to retrieve Köster et al. (2005), then citationGraph to map 429 citing papers on LPL regulation, and findSimilarPapers for Stitziel et al. (2016) variants.
Analyze & Verify
Analysis Agent applies readPaperContent on Musunuru et al. (2010) to extract exome data, verifyResponse with CoVe against GWAS claims, and runPythonAnalysis to plot triglyceride reductions from ANGPTL4/3 mutants using pandas on supplement tables, graded by GRADE for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in adipose vs. muscle LPL effects via contradiction flagging across Köster (2005) and Stitziel (2016), then Writing Agent uses latexEditText for mechanism review, latexSyncCitations for 10+ refs, and latexCompile for figure-inclusive manuscript; exportMermaid diagrams ANGPTL4-LPL pathways.
Use Cases
"Compare triglyceride levels in ANGPTL4 knockout vs wildtype mice from Köster 2005"
Analysis Agent → readPaperContent(Köster et al., 2005) → runPythonAnalysis(pandas plot of LPL activity data) → matplotlib graph of fasting lipolysis differences.
"Write LaTeX review on ANGPTL4 GWAS coronary risk with citations"
Synthesis Agent → gap detection(Stitziel 2016 + Musunuru 2010) → Writing Agent latexEditText(draft) → latexSyncCitations(ANGPTL4 refs) → latexCompile(PDF review section).
"Find code for ANGPTL4 lipid simulation models"
Research Agent → paperExtractUrls(recent lipid metabolism papers) → paperFindGithubRepo → githubRepoInspect(Angptl4 scripts) → runPythonAnalysis(lipid kinetics simulation).
Automated Workflows
Deep Research workflow scans 50+ ANGPTL4 papers via searchPapers → citationGraph → structured report on LPL inhibition evolution (Köster 2005 to Stitziel 2016). DeepScan applies 7-step CoVe to verify triglyceride claims in Ginsberg et al. (2021). Theorizer generates hypotheses on ANGPTL4-ANGPTL3 synergy from Musunuru (2010) abstracts.
Frequently Asked Questions
What defines ANGPTL4's role in lipid metabolism?
ANGPTL4 inhibits LPL in adipose tissue during fasting to limit triglyceride hydrolysis and promote lipolysis (Köster et al., 2005).
What methods study ANGPTL4 functions?
Researchers use transgenic overexpression, targeted disruption in mice, and human exome sequencing/GWAS for variants (Köster et al., 2005; Musunuru et al., 2010; Stitziel et al., 2016).
What are key papers on ANGPTL4?
Köster et al. (2005, 429 citations) shows Angptl4 disruption regulates triglycerides; Stitziel et al. (2016, 497 citations) links loss-of-function to coronary protection.
What open problems exist in ANGPTL4 research?
Tissue-specific inhibitors avoiding muscle LPL effects and combined ANGPTL3/4 therapies for hypertriglyceridemia remain undeveloped (Dewey et al., 2017; Ginsberg et al., 2021).
Research Lipid metabolism and disorders with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching ANGPTL4 Role in Lipid Metabolism with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Lipid metabolism and disorders Research Guide